|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2002-4-22
|
|
pubmed:abstractText |
Patients with end-stage renal disease (ESRD) undergoing hemodialysis have severe alterations in cell-mediated immunity (CMI) that increases their risk of contracting chronic hepatitis B virus (HBV) infection and decreases their protective responses to HBV vaccine. In an effort to improve the humoral response to an accelerated HBV vaccine protocol in these patients, the ability of an immunomodulator, AM3, to improve seroconversion was investigated.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0085-2538
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
61
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1845-52
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:11967036-Adjuvants, Immunologic,
pubmed-meshheading:11967036-Aged,
pubmed-meshheading:11967036-Calcium Phosphates,
pubmed-meshheading:11967036-Double-Blind Method,
pubmed-meshheading:11967036-Female,
pubmed-meshheading:11967036-Follow-Up Studies,
pubmed-meshheading:11967036-Glycopeptides,
pubmed-meshheading:11967036-Hepatitis B, Chronic,
pubmed-meshheading:11967036-Hepatitis B Antibodies,
pubmed-meshheading:11967036-Hepatitis B Vaccines,
pubmed-meshheading:11967036-Humans,
pubmed-meshheading:11967036-Kidney Failure, Chronic,
pubmed-meshheading:11967036-Male,
pubmed-meshheading:11967036-Middle Aged,
pubmed-meshheading:11967036-Renal Dialysis
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
AM3 (Inmunoferón) as an adjuvant to hepatitis B vaccination in hemodialysis patients.
|
|
pubmed:affiliation |
Nephrology Service, Gregorio Marañón Hospital, Madrid, Spain.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Multicenter Study
|
